CN1526700A - 枸橼酸莫沙必利重要中间体的合成工艺 - Google Patents
枸橼酸莫沙必利重要中间体的合成工艺 Download PDFInfo
- Publication number
- CN1526700A CN1526700A CNA031119131A CN03111913A CN1526700A CN 1526700 A CN1526700 A CN 1526700A CN A031119131 A CNA031119131 A CN A031119131A CN 03111913 A CN03111913 A CN 03111913A CN 1526700 A CN1526700 A CN 1526700A
- Authority
- CN
- China
- Prior art keywords
- important intermediate
- acid
- feature
- preparation
- preparation technology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 229960004085 mosapride Drugs 0.000 title claims abstract description 17
- 230000015572 biosynthetic process Effects 0.000 title description 6
- 238000003786 synthesis reaction Methods 0.000 title description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims abstract description 14
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000007062 hydrolysis Effects 0.000 claims abstract description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 4
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960004909 aminosalicylic acid Drugs 0.000 claims abstract description 3
- 230000032050 esterification Effects 0.000 claims abstract description 3
- 238000005886 esterification reaction Methods 0.000 claims abstract description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 claims description 5
- 239000012021 ethylating agents Substances 0.000 claims 1
- -1 ethylation Chemical compound 0.000 abstract description 17
- 238000003756 stirring Methods 0.000 abstract description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 239000000543 intermediate Substances 0.000 abstract 3
- 230000021736 acetylation Effects 0.000 abstract 1
- 238000006640 acetylation reaction Methods 0.000 abstract 1
- 239000003513 alkali Substances 0.000 abstract 1
- 238000005660 chlorination reaction Methods 0.000 abstract 1
- 230000006203 ethylation Effects 0.000 abstract 1
- 238000006200 ethylation reaction Methods 0.000 abstract 1
- 230000020477 pH reduction Effects 0.000 abstract 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229960004756 ethanol Drugs 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229940064734 aminobenzoate Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N aniline-p-carboxylic acid Natural products NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- ANQWOEYKZJYUFB-UHFFFAOYSA-N [Na].NOC1=CC=CC=C1C(O)=O Chemical compound [Na].NOC1=CC=CC=C1C(O)=O ANQWOEYKZJYUFB-UHFFFAOYSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- KYKHSUPYKKPWJV-UHFFFAOYSA-N COC(C1=C(C=CC=C1)O)=O.C(C)(=O)NC1=CC(=C(C=C1)[As](O)(O)=O)O Chemical class COC(C1=C(C=CC=C1)O)=O.C(C)(=O)NC1=CC(=C(C=C1)[As](O)(O)=O)O KYKHSUPYKKPWJV-UHFFFAOYSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- DHOQOKWZEBHCJT-UHFFFAOYSA-N fluorobenzene;methanamine Chemical compound NC.FC1=CC=CC=C1 DHOQOKWZEBHCJT-UHFFFAOYSA-N 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- HWVSNYIAZJHZFQ-UHFFFAOYSA-M sodium;4-aminobenzoate;hydrate Chemical group O.[Na+].NC1=CC=C(C([O-])=O)C=C1 HWVSNYIAZJHZFQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03111913 CN1226295C (zh) | 2003-03-03 | 2003-03-03 | 枸橼酸莫沙必利的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03111913 CN1226295C (zh) | 2003-03-03 | 2003-03-03 | 枸橼酸莫沙必利的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1526700A true CN1526700A (zh) | 2004-09-08 |
CN1226295C CN1226295C (zh) | 2005-11-09 |
Family
ID=34283555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03111913 Expired - Lifetime CN1226295C (zh) | 2003-03-03 | 2003-03-03 | 枸橼酸莫沙必利的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1226295C (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102320986A (zh) * | 2011-07-25 | 2012-01-18 | 武汉武药科技有限公司 | 一种氯吡格雷中间体的制备方法 |
CN101565381B (zh) * | 2009-06-01 | 2013-07-24 | 重庆英斯凯化工有限公司 | 2-烷氧基-4-氨基-5-氯苯甲酸的制备方法 |
CN101538217B (zh) * | 2008-03-20 | 2015-04-15 | 成都弘达药业有限公司 | 2-乙氧基-4-氨基-5-氯苯甲酸的合成新方法及其中间体 |
CN104693137A (zh) * | 2013-12-10 | 2015-06-10 | 沈阳药科大学 | 一种莫沙必利活性代谢物 |
CN104693064A (zh) * | 2013-12-10 | 2015-06-10 | 沈阳药科大学 | 莫沙必利的活性代谢物 |
CN108129414A (zh) * | 2018-02-09 | 2018-06-08 | 鲁南制药集团股份有限公司 | 一种枸橼酸莫沙必利中间体的制备方法 |
CN108341788A (zh) * | 2018-02-09 | 2018-07-31 | 鲁南制药集团股份有限公司 | 一种枸橼酸莫沙必利中间体及用途 |
CN111848432A (zh) * | 2020-07-15 | 2020-10-30 | 广药白云山化学制药(珠海)有限公司 | 一种对氨基水杨酸的制备方法 |
CN112225708A (zh) * | 2020-12-14 | 2021-01-15 | 上海翰森生物医药科技有限公司 | 一种莫沙必利中间体的制备方法 |
-
2003
- 2003-03-03 CN CN 03111913 patent/CN1226295C/zh not_active Expired - Lifetime
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101538217B (zh) * | 2008-03-20 | 2015-04-15 | 成都弘达药业有限公司 | 2-乙氧基-4-氨基-5-氯苯甲酸的合成新方法及其中间体 |
CN101565381B (zh) * | 2009-06-01 | 2013-07-24 | 重庆英斯凯化工有限公司 | 2-烷氧基-4-氨基-5-氯苯甲酸的制备方法 |
CN102320986A (zh) * | 2011-07-25 | 2012-01-18 | 武汉武药科技有限公司 | 一种氯吡格雷中间体的制备方法 |
CN102320986B (zh) * | 2011-07-25 | 2014-06-25 | 武汉武药科技有限公司 | 一种氯吡格雷中间体的制备方法 |
CN104693137A (zh) * | 2013-12-10 | 2015-06-10 | 沈阳药科大学 | 一种莫沙必利活性代谢物 |
CN104693064A (zh) * | 2013-12-10 | 2015-06-10 | 沈阳药科大学 | 莫沙必利的活性代谢物 |
CN108129414A (zh) * | 2018-02-09 | 2018-06-08 | 鲁南制药集团股份有限公司 | 一种枸橼酸莫沙必利中间体的制备方法 |
CN108341788A (zh) * | 2018-02-09 | 2018-07-31 | 鲁南制药集团股份有限公司 | 一种枸橼酸莫沙必利中间体及用途 |
CN108129414B (zh) * | 2018-02-09 | 2020-12-08 | 鲁南制药集团股份有限公司 | 一种枸橼酸莫沙必利中间体的制备方法 |
CN111848432A (zh) * | 2020-07-15 | 2020-10-30 | 广药白云山化学制药(珠海)有限公司 | 一种对氨基水杨酸的制备方法 |
CN112225708A (zh) * | 2020-12-14 | 2021-01-15 | 上海翰森生物医药科技有限公司 | 一种莫沙必利中间体的制备方法 |
CN112225708B (zh) * | 2020-12-14 | 2021-04-09 | 上海翰森生物医药科技有限公司 | 一种莫沙必利中间体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1226295C (zh) | 2005-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103058989B (zh) | 一种α-硫辛酸的制备方法 | |
CN1466570A (zh) | 晶体和纯莫达非尼及其制备方法 | |
CN1226295C (zh) | 枸橼酸莫沙必利的制备方法 | |
CN113233975B (zh) | 一种贝派地酸的制备方法 | |
CN1031939C (zh) | 催化下分子重排制备布洛芬的工艺 | |
CN103724336B (zh) | 一种新型抗凝血药物的合成方法 | |
CN108059601A (zh) | 一种制备3-氨基-1-金刚烷醇的工艺 | |
CN1623987A (zh) | 托拉塞米的制备方法 | |
CN101037445A (zh) | 一种具有潜在生物活性的咪唑并[2,1-b]-1,3,4-噻二唑衍生物及其合成方法 | |
CN101492413B (zh) | 卡洛芬的精制方法 | |
CN115417767A (zh) | 一种卡龙酸酐及其中间体的制备方法 | |
CN101892276B (zh) | 一种阿托伐他汀钙化合物及其新方法 | |
CN102010345A (zh) | 一种动态动力学拆分制备d-苯丙氨酸的方法 | |
CN100522936C (zh) | 2,4-二氯-5-磺酰胺基苯甲酸的合成方法 | |
CN1279035C (zh) | 光学对映体6-氟-3,4-二氢-2h-1-苯骈吡喃-2-羧酸及6-氟-3,4-二氢-2h-1-苯骈吡喃-2-羧酸酯的合成方法 | |
CN110003075A (zh) | 一种2-(4-羟基-2-氧代-1-吡咯烷基)乙酰胺的制备方法 | |
CN1915974A (zh) | 氨氯地平的拆分方法 | |
CN1082045C (zh) | α-苯偶姻肟的合成方法 | |
CN106749030B (zh) | 一种用于icu镇静镇痛的盐酸右美托咪定的制备方法 | |
CN102827174A (zh) | 一种醛糖还原酶抑制剂非达司他的制备方法 | |
CN104693110A (zh) | 一种含拉西地平的组合物制备方法 | |
CN102887851B (zh) | 化合物3,5-二甲基-1h-吡咯-2,4-二甲醛及其制备方法 | |
WO2005016937A1 (fr) | Procede de synthese de 6-chloro-4-hydroxy-2-methyl-2h-thienol(2,3-e)-1,2-thiazine-1,1-dioxyde-3-carboxylate | |
CN102391170A (zh) | 一种n,n-二烯丙基-5-甲氧基色胺盐酸盐的制备方法 | |
CN109180511A (zh) | 一种盐酸丁卡因的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20040908 Assignee: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2013370000261 Denomination of invention: Synthesis of Important intermediate for mosapride citrate Granted publication date: 20051109 License type: Exclusive License Record date: 20131210 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161228 Address after: 276005 Hongqi Road, Shandong, Linyi, No. 209 Patentee after: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Address before: 276005 Hongqi Road, Shandong, Linyi, No. 209 Patentee before: LUNAN PHARMACEUTICAL Group Corp. |
|
CX01 | Expiry of patent term |
Granted publication date: 20051109 |
|
CX01 | Expiry of patent term |